ASCO names first VP/general counsel
Dina Michels joins the American Society of Clinical Oncology as its first Vice President and General Counsel, the Society announced June 7. Michels will work with the Board of Directors and staff to provide legal counsel. Most recently Michels was a partner with Ropes & Gray LLP...
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.